Atellica IM CA 19-9 (50 Test)-In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human serum using the Atellica CI and Atellica IM Analyzers SMN: 10995490
Published September 18, 2024 · Recall initiated: July 26, 2024
Summary
FDA records medical device Class II recall Z-3100-2024, published September 18, 2024 and initiated July 26, 2024. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Ongoing; Lot: UDI-DI: (01)00630414598178(10)55974535(17)20240914 Kit Lot: 55974535, 55975535. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Siemens Healthcare Diagnostics, Inc.
- Distributor
- Worldwide - US Nationwide distribution
- Lot
- UDI-DI: (01)00630414598178(10)55974535(17)20240914 Kit Lot: 55974535, 55975535
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAAtellica CH Revised C-Reactive Protein (RCRP); Siemens Material Number (SMN): 11537223;October 7, 2026
- FDABeckman Coulter, Emit 2000 Quinidine Assay REF: OSR4Q229 Contents: R1: 2 x 23 mL;R2 2x13 mLAugust 26, 2026
- FDASyva EMIT 2000 Quinidine Assay REF: 4Q019UL Contents: 1x28 mL, 1x14mLAugust 26, 2026
- FDASyva Emit tox Serum Tricyclic Antidepressant Calibrator/Controls SMN 10445390 Catalog No. 7C219ULAugust 12, 2026
- FDASpacelabs Ultraview DM4 Vital Signs Monitor (all variations -M, -N, -MF, -NF, -MW, -NW, -MFW, -NFW), ModelSeptember 18, 2024
- FDAAtellica IM CA 19-9 (250 Test)- In vitro diagnostic use in the quantitative measurement of the CA 19-9September 18, 2024
Questions about this recall
Was Atellica IM CA 19-9 (50 Test)-In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human serum using the Atellica CI and Atellica IM Analyzers SMN: 10995490 recalled?
Yes. FDA published recall Z-3100-2024 on September 18, 2024. Reported hazard: Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.
What should I do if I have this product?
Voluntary: Firm initiated · Letter